It’s an election year, and ACR staff are excited about the possibility of moving key initiatives, such as Medicare reimbursement, across the finish line. But they need members’ help to do so.
Government Affairs: A Marathon, Not a Sprint
Government Affairs Committee member Donald Miller, PharmD, reflects on the effects of rheumatology advocacy work over time, noting that progress is often easier to see from the distance.
ACR Delegation to Lead Several Resolutions at June AMA House of Delegates Meeting
The ACR will lead five other specialty societies on a resolution supporting pediatric specialty care and will co-lead resolutions addressing Medicare Advantage Part B drug coverage, white bagging mandates, state prescription drug affordability boards and impacts of alternative funding programs on access to care.
FTC Bans Noncompete Agreements: What Rheumatologists Need to Know
The ACR applauds the FTC’s recent ban on most noncompete agreements. The ruling is a step in the right direction toward a more competitive market for healthcare workers and their services.
Commercial Payers Update Reimbursement for Underwater Infliximab Biosimilars
Three commercial health insurance payers have increased reimbursement for infliximab biosimilars in response to concerns that formulary requirements are leaving practices underwater.
Congressional Action Partially Addresses Medicare Cuts
The newest funding package reduces the latest cut to Medicare reimbursement from 3.4% to 1.68%. Although rheumatologists are faring better under Medicare in 2024, broader reforms remain the ACR’s highest priority regarding Medicare payments to physicians.
RheumPAC’s Role in the ACR’s Advocacy Efforts
In an election year, it is critical that the ACR’s non-partisan political action committee be well positioned to support our congressional champions. Learn more about RheumPAC and its role in the ACR’s advocacy efforts.
Updates from the ACR Insurance Subcommittee
The Insurance Subcommittee is working to address coverage and reimbursement challenges facing rheumatology practices, including issues related to biosimilar use, in-office treatments and the new G2211 code.
The Biosimilar Economic Conundrum: Where We Stand
Reimbursement has fallen below acquisition price for some biosimilar versions of infliximab, forcing practices and patients to make difficult decisions. The ACR is working to change this.
ACR Advocacy Staff Outline Victories, Challenges from a Busy Year
SAN DIEGO—In an advocacy update session at ACR Convergence 2023, ACR staff described progress in multiple priority areas, including access to care and workforce issues.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 10
- Next Page »